Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

Affimed Reports Financial Results for Fourth Quarter and Year End 2017

GlobeNewswire March 20, 2018

Affimed N.V. to Host Earnings Call

Accesswire March 20, 2018

Earnings Scheduled For March 20, 2018

Benzinga.com  March 20, 2018

Affimed Appoints Dr. Leila Alland as Chief Medical Officer

GlobeNewswire March 19, 2018

Affimed to Present Data on AFM24 at AACR Annual Meeting 2018

GlobeNewswire March 15, 2018

Affimed Announces Fourth Quarter and Year End 2017 Financial Results and Corporate Update Conference Call

GlobeNewswire March 13, 2018

Affimed to Present at the Cowen and Company 38th Annual Health Care Conference

GlobeNewswire March 8, 2018

Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 15, 2018

Mid-Day Market Update: GNC Climbs Following Announcement of $300M Investment From Harbin Pharmaceuticals; Helios And Matheson Shares Drop

Benzinga.com  February 13, 2018

9 Stocks Moving In Monday's After-Hours Session

Benzinga.com  February 12, 2018

Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas

GlobeNewswire February 1, 2018

Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH

GlobeNewswire December 11, 2017

Affimed to Present at the Jefferies 2017 London Healthcare Conference

GlobeNewswire November 15, 2017

Affimed Reports Financial Results for Third Quarter 2017

GlobeNewswire November 7, 2017

Affimed to Present at the 26th Annual Credit Suisse Healthcare Conference

GlobeNewswire November 2, 2017

Affimed to Present Clinical and Preclinical Data on Immune Cell Engagers at ASH

GlobeNewswire November 1, 2017

Affimed Announces Third Quarter 2017 Financial Results and Corporate Update Conference Call

GlobeNewswire October 30, 2017

AbCheck and Molecular Templates Announce Collaboration to Discover Therapeutic Oncology Leads

GlobeNewswire October 25, 2017

Affimed to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

GlobeNewswire September 22, 2017

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  September 21, 2017